Agomab reports positive OLE data for ontunisertib in Crohn's bowel stricturesOct 1Clinical readoutAgomAb Therapeutics NVontunisertib
Agomab reports first-half 2026 results, confirms FDA alignment on Crohn's trial designAug 6Clinical readoutAgomAb Therapeutics NV
Agomab registers Phase 2b trial of ontunisertib in fibrostenosing Crohn's diseaseJul 6Trial updateAgomAb Therapeutics NVontunisertib
Agomab Spain registers Phase 1 mass balance trial of ontunisertib in healthy volunteersJun 29Trial updateAgomAb Therapeutics NVontunisertib
Sign inSign in